Introduced the first automated flash protocol.
Introduced the concept of near-patient signal digitization with the UTAS’s ultra-sensitive signal acquisition amplifier, the UBA-4204 Digital Biomedical Amplifier.
The UBA was the industry’s first fiber optic coupled amplifier that conditioned and digitized the patient’s electrical response in a battery-powered unit, producing clear signals by the safest possible means.
Patented timing methods among color LEDs to generate the most consistent white-light flashes, helping transition away from xenon flash tube technology to the more reliable LED technology.
Invented the patented Sensor Strip electrode array, which adhere to the skin beneath the eye rather than touching the eye, improves patient safety and convenience.
Patented real-time pupil size compensation in flash stimuli enables consistent results without the need to artificially dilate the pupil.
Patented the use of combining data from multiple brightness flicker ERGs and pupillography to help assess retinopathy.
Introduced the RETeval device in 2013, that implements the patented technology above. It is the world’s first and only hand-held, battery powered, portable, non-invasive, fully ISCEVcompliant ERG device for use on dilated or non-dilated eyes. The RETeval device is also CE Marked and FDA cleared.
LKC holds six U.S. patents and foreign counterparts for its product line.
LKC participates in scientific research, publishing papers in peer-reviewed journals.
LKC introduced the concept of ring-ratios for hydroxychloroquine toxicity monitoring, which is now in the AAO guidelines for monitoring for that issue.
LKC authored a publication that is listed as a 2017-2018 top article by the journal Documenta Ophthalmologica, the official journal of the International Society for Clinical Electrophysiology and Vision.
LKC has received four Small Business Innovative Research (SBIR) Grants from the National Institutes of Health.

LKC Technologies, Inc. services

Customer Support